Scharf Investments LLC bought a new position in Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 491,450 shares of the company's stock, valued at approximately $5,096,000.
A number of other institutional investors have also recently modified their holdings of HLN. Nuveen LLC purchased a new stake in shares of Haleon in the first quarter worth $58,870,000. Millennium Management LLC grew its stake in shares of Haleon by 697.2% in the first quarter. Millennium Management LLC now owns 4,216,504 shares of the company's stock worth $43,388,000 after acquiring an additional 3,687,613 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Haleon by 22.0% in the first quarter. Wellington Management Group LLP now owns 18,700,480 shares of the company's stock worth $192,428,000 after acquiring an additional 3,372,155 shares during the last quarter. Sculptor Capital LP grew its stake in shares of Haleon by 22.1% in the first quarter. Sculptor Capital LP now owns 10,849,868 shares of the company's stock worth $111,645,000 after acquiring an additional 1,962,770 shares during the last quarter. Finally, Jane Street Group LLC boosted its position in shares of Haleon by 933.1% during the first quarter. Jane Street Group LLC now owns 2,155,716 shares of the company's stock valued at $22,182,000 after buying an additional 1,947,050 shares during the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several equities research analysts recently commented on the company. The Goldman Sachs Group raised Haleon from a "neutral" rating to a "buy" rating in a research report on Wednesday, September 10th. Wall Street Zen cut Haleon from a "buy" rating to a "hold" rating in a research report on Saturday, July 12th. BNP Paribas raised Haleon to a "strong-buy" rating in a research report on Tuesday, May 27th. BNP Paribas Exane raised Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price objective on the stock in a research report on Tuesday, May 27th. Finally, Barclays cut Haleon from an "overweight" rating to an "equal weight" rating in a research report on Tuesday, September 16th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, Haleon currently has a consensus rating of "Moderate Buy" and a consensus price target of $12.33.
Get Our Latest Stock Report on HLN
Haleon Stock Down 0.9%
NYSE HLN opened at $9.16 on Monday. The stock's 50-day moving average price is $9.66 and its 200-day moving average price is $10.16. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.48. Haleon PLC Sponsored ADR has a 52 week low of $8.86 and a 52 week high of $11.42. The company has a market capitalization of $40.99 billion, a P/E ratio of 23.49, a price-to-earnings-growth ratio of 2.71 and a beta of 0.23.
Haleon Increases Dividend
The firm also recently announced a semi-annual dividend, which was paid on Thursday, September 18th. Investors of record on Friday, August 15th were paid a dividend of $0.0555 per share. This is a boost from Haleon's previous semi-annual dividend of $0.05. The ex-dividend date of this dividend was Friday, August 15th. This represents a yield of 190.0%. Haleon's dividend payout ratio is 28.21%.
Haleon Profile
(
Free Report)
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Featured Articles
Want to see what other hedge funds are holding HLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haleon PLC Sponsored ADR (NYSE:HLN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
